Patients in whom the treatment was assessed as effective [achieved complete response (CR)/partial response (PR) or showed a trend of hematological improvement] at Week 26 entered the extension phase to continue treatment until the product became commercially available.
← all excerpts
Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.
1
—
—